Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER AF-PCI
NL-OMON43906Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinically significant bleeding at 12 months. Started Dec 2013; status: active, not recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON43906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43906.